We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

85 hedge funds and large institutions have $111M invested in Eledon Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 15

4% more ownership

Funds ownership: 64.21% → 68.21% (+4%)

2% more funds holding

Funds holding: 83 → 85 (+2)

8% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 26

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

15% less capital invested

Capital invested by funds: $130M → $111M (-$19.7M)

40% less call options, than puts

Call options by funds: $134K | Put options by funds: $223K

Holders
85
Holders Change
+2
Holders Change %
+2.41%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
28
Increased
21
Reduced
15
Closed
26
Calls
$134K
Puts
$223K
Net Calls
-$89K
Net Calls Change
+$157K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.81M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.15M
3
State Street
State Street
Massachusetts
+$1.18M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.1M
5
Northern Trust
Northern Trust
Illinois
+$970K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.92M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.7M
3
BOCH
Blue Owl Capital Holdings
New York
-$1.47M
4
SFM
Sphera Funds Management
Israel
-$1.04M
5
SSA
Schonfeld Strategic Advisors
New York
-$961K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
26
Boothbay Fund Management
New York
$796K -$55.8K -18,593 -6%
Renaissance Technologies
27
Renaissance Technologies
New York
$517K +$204K +67,900 +55%
Charles Schwab
28
Charles Schwab
California
$480K +$442K +147,262 +491%
Millennium Management
29
Millennium Management
New York
$465K -$1.92M -639,207 -79%
Citadel Advisors
30
Citadel Advisors
Florida
$413K +$175K +58,463 +62%
Dimensional Fund Advisors
31
Dimensional Fund Advisors
Texas
$370K +$60.8K +20,281 +17%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$364K +$403K +134,322 New
UBS Group
33
UBS Group
Switzerland
$342K +$309K +103,041 +444%
EAM
34
Exome Asset Management
New York
$309K – – –
Barclays
35
Barclays
United Kingdom
$276K +$95.6K +31,878 +46%
Marshall Wace
36
Marshall Wace
United Kingdom
$257K +$227K +75,572 +394%
N
37
Nuveen
North Carolina
$207K +$229K +76,292 New
DP
38
Diadema Partners
New Jersey
$175K – – –
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$152K +$168K +56,050 New
ISL
40
Ingalls & Snyder LLC
New York
$141K – – –
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$109K +$121K +40,193 New
Wells Fargo
42
Wells Fargo
California
$101K +$111K +37,156 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$98.6K +$109K +36,400 New
MIM
44
MetLife Investment Management
New Jersey
$98.3K +$109K +36,264 New
PCM
45
Prelude Capital Management
New York
$97.9K -$9.69K -3,230 -8%
American Century Companies
46
American Century Companies
Missouri
$96.5K +$107K +35,592 New
BCM
47
Bridgeway Capital Management
Texas
$90.5K – – –
Mirae Asset Global ETFs Holdings
48
Mirae Asset Global ETFs Holdings
Hong Kong
$86.9K +$96.2K +32,052 New
MIM
49
Marco Investment Management
Georgia
$82.2K – – –
HFS
50
Howard Financial Services
Texas
$81.3K +$90K +30,000 New
1
2
3 4 5

ELDN Hedge Fund Activity: Q2 2025 in Review

85 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2025, worth a combined $111M — down 15% from $130M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new ELDN positions and 26 closed out — a net gain of 2 holders — while 21 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $7.81M. The largest seller was Millennium Management, cutting an estimated $1.92M.

  • 85 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2025, up from 83 in Q1 2025.
  • Funds reported $111M of Eledon Pharmaceuticals stock for Q2 2025, down 15% quarter-over-quarter.
  • 28 funds opened new Eledon Pharmaceuticals positions in Q2 2025 and 26 closed out, a net change of +2 holders.
  • The largest Eledon Pharmaceuticals buyer in Q2 2025 was BlackRock, an estimated $7.81M added.
  • The largest Eledon Pharmaceuticals seller in Q2 2025 was Millennium Management, an estimated $1.92M sold.

Based on aggregated 13F filings for Q2 2025.